Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Hilscher

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Computers in Biology and Medicine|July 5, 2025
In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitorsFady Baselious, Sebastian Hilscher, Lukas Handke, et al.
International Journal of Molecular Sciences|January 27, 2024
Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 InhibitorFady Baselious, Sebastian Hilscher, Dina Robaa, et al.
ACS Omega|November 3, 2025
Substrate-Guided Development of HDAC11-Selective Inhibitors Featuring α‑Amino Amide Zinc-Binding GroupsSebastian Hilscher, Marat Meleshin, Fady Baselious, et al.
International Journal of Molecular Sciences|April 28, 2023
Continuous Fluorescent Sirtuin Activity Assay Based on Fatty Acylated LysinesMatthes Zessin, Marat Meleshin, Sebastian Hilscher, et al.
Archiv Der Pharmazie|July 12, 2024
Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activityFady Baselious, Sebastian Hilscher, Sven Hagemann, et al.
Archiv Der Pharmazie|September 18, 2024
Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cellsFrancesco Berluti, Fady Baselious, Sven Hagemann, et al.
Archiv Der Pharmazie|November 6, 2023
Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cellsMohamed Abdelsalam, Mariia Zmyslia, Karin Schmidtkunz, et al.
Bioorganic Chemistry|April 19, 2025
Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluationNoreen Hemida, Dalia S El-Gamil, Ahmed K ElHady, et al.
RSC Medicinal Chemistry|April 21, 2025
Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancerAya Fathy, Amro Allam, Ahmed K ElHady, et al.
ACS Omega|February 16, 2026
Capsaicin-Inspired Hydroxamate Hybrids as Selective HDAC6 Inhibitors with Antiproliferative Activity in Hematological MalignanciesLara Gimenez Borges, Thais Nascimento de Oliveira Alves, Sandra Valeria Vassiliades, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Computers in Biology and Medicine|July 5, 2025
In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitorsFady Baselious, Sebastian Hilscher, Lukas Handke, et al.
International Journal of Molecular Sciences|January 27, 2024
Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 InhibitorFady Baselious, Sebastian Hilscher, Dina Robaa, et al.
ACS Omega|November 3, 2025
Substrate-Guided Development of HDAC11-Selective Inhibitors Featuring α‑Amino Amide Zinc-Binding GroupsSebastian Hilscher, Marat Meleshin, Fady Baselious, et al.
International Journal of Molecular Sciences|April 28, 2023
Continuous Fluorescent Sirtuin Activity Assay Based on Fatty Acylated LysinesMatthes Zessin, Marat Meleshin, Sebastian Hilscher, et al.
Archiv Der Pharmazie|July 12, 2024
Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activityFady Baselious, Sebastian Hilscher, Sven Hagemann, et al.
Archiv Der Pharmazie|September 18, 2024
Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cellsFrancesco Berluti, Fady Baselious, Sven Hagemann, et al.
Archiv Der Pharmazie|November 6, 2023
Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cellsMohamed Abdelsalam, Mariia Zmyslia, Karin Schmidtkunz, et al.
Bioorganic Chemistry|April 19, 2025
Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluationNoreen Hemida, Dalia S El-Gamil, Ahmed K ElHady, et al.
RSC Medicinal Chemistry|April 21, 2025
Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancerAya Fathy, Amro Allam, Ahmed K ElHady, et al.
ACS Omega|February 16, 2026
Capsaicin-Inspired Hydroxamate Hybrids as Selective HDAC6 Inhibitors with Antiproliferative Activity in Hematological MalignanciesLara Gimenez Borges, Thais Nascimento de Oliveira Alves, Sandra Valeria Vassiliades, et al.
Pageof 2